Brown & Brown, Inc. has been recognized as a 2027 Military Friendly® Employer for the third year in a row and received the Silver Award for the second consecutive year. This designation highlights the company's commitment to attracting, developing, and supporting veterans and military families, reflecting its culture of excellence and service. The award is based on a survey evaluating recruitment, retention, turnover, and advancement of veterans. Brown & Brown continues to emphasize the value veterans bring to its workforce and its dedication to creating opportunities for them to thrive.
Brown & Brown, Inc. earned the 2027 Military Friendly® Employer designation and Silver Award. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 12, 2026 03:31 WIB: out of 142 priced US stocks, 96 rose and 45 fell. Notable movers include BTBT at USD 0.78 with a 7.20% increase and a typical hold time of 15 days on Pluang.
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...
PepGen Inc. stock surged over 100% following positive Phase 2 top-line results for its DM1 treatment PGN-EDODM1, which showed a 46.5% mean splicing correction and functional improvements with good safety at 10 mg/kg over four doses. Despite these pro...
